Literature DB >> 15052515

Severe and uncommon involuntary movement disorders due to psychotropic drugs.

S Stübner1, E Rustenbeck, R Grohmann, G Wagner, R Engel, G Neundörfer, H-J Möller, H Hippius, E Rüther.   

Abstract

Disorders of involuntary movement due to psychotropic drugs pose a major problem when treating mentally ill patients. These adverse drug reactions (ADR) frequently undermine the patients' compliance and may have serious consequences as well. The drug safety program in psychiatry AMSP (Arzneimittelsicherheit in der Psychiatrie) surveyed a population of 122,562 patients between 1993 and 2000, and documented 129 especially severe or uncommon involuntary movement disorders (IMD): 9 episodes of severe acute dyskinesia, 32 of severe Parkinsonism, 5 of especially severe akathisia, 16 of 'atypical dyskinesia', 38 of Pisa syndrome, 6 of catatonic neuroleptic syndrome, 15 of neuroleptic malignant syndrome, and 8 of tardive dyskinesia. The epidemiological data for this population were systematically analyzed as regards the patient's history of medication, comedication, and clinical course. In those cases, in which a certain drug was imputed to cause an ADR alone and the causal relationship was rated as definite or probable, typical neuroleptics with mainly antipsychotic effects showed a relatively high incidence of 0.1047 %, those with hypnotic-sedative effect a lower incidence of 0.0198 %, and the atypical neuroleptics an incidence of 0.0567 %. This difference was highly significant in an chi (2)-analysis (chi (2) = 18.81, df = 2, p < 0.0001). Our data provide important information on the frequency, severity, and the consequences of ARD for the patients' compliance, and thus are of clinical interest.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15052515     DOI: 10.1055/s-2004-815511

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  30 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

2.  Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.

Authors:  Michael Schneider; Johannes Regente; Timo Greiner; Stephanie Lensky; Stefan Bleich; Sermin Toto; Renate Grohmann; Susanne Stübner; Martin Heinze
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-11-30       Impact factor: 5.270

Review 3.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

4.  Neuroleptic Malignant Syndrome Associated with Lithium Toxicity.

Authors:  Vaibhav Patil; Rishab Gupta; Rohit Verma; Yatan Pal Singh Balhara
Journal:  Oman Med J       Date:  2016-07

5.  Severe parkinsonism under treatment with antipsychotic drugs.

Authors:  Katrin Druschky; Stefan Bleich; Renate Grohmann; Rolf R Engel; Sermin Toto; Alexandra Neyazi; Barbara Däubl; Susanne Stübner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-23       Impact factor: 5.270

Review 6.  Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis.

Authors:  Marco Solmi; G Giorgio Pigato; Beatrice Roiter; Argentina Guaglianone; Luca Martini; Michele Fornaro; Francesco Monaco; Andrè F Carvalho; Brendon Stubbs; Nicola Veronese; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

7.  Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study.

Authors:  R Grohmann; R R Engel; H-J Möller; E Rüther; J W van der Velden; S Stübner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-09       Impact factor: 5.270

8.  Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study.

Authors:  Josef Bäuml; Gabriele Pitschel-Walz; Anja Volz; Sandra Lüscher; Michael Rentrop; Werner Kissling; Thomas Jahn
Journal:  Schizophr Bull       Date:  2016-03-08       Impact factor: 9.306

9.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12

10.  Neuroleptic malignant syndrome: a review for neurohospitalists.

Authors:  Brian D Berman
Journal:  Neurohospitalist       Date:  2011-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.